OncoMatch/Clinical Trials/NCT06624371
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Is NCT06624371 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Atovaquone for high-grade glioma.
Treatment: Atovaquone — The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Biomarker criteria
Required: H3-3A K27M mutation
diffuse midline glioma with altered H3K27 (DMG, WHO Grade 4)
Disease stage
Grade: WHO Grade 3WHO Grade 4 (WHO)
pediatric high-grade glioma (pHGG, WHO Grade 3 or 4) or diffuse midline glioma with altered H3K27 (DMG, WHO Grade 4)
Demographics
Prior therapy
Must have received: radiation therapy — standard-of-care
Patients must have previously undergone standard-of-care treatment including surgery, radiation, and/or first-line adjuvant chemotherapy before the experimental treatment (atovaquone).
Cannot have received: atovaquone (atovaquone)
without prior atovaquone exposure
Lab requirements
Blood counts
absolute neutrophil count > 1,000/mcL; platelets > 100,000/mcL; hemoglobin > 8g/dL
Kidney function
creatinine within normal institutional limits for age OR creatinine clearance > 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal
Liver function
Total bilirubin ≤ 2x ULN; AST (SGOT) and ALT (SGPT) ≤ 225 U/L (5x ULN); ULN for AST and ALT is 45 U/L
Patients must have normal organ and marrow function as defined below: absolute neutrophil count > 1,000/mcL; platelets > 100,000/mcL; hemoglobin > 8g/dL; Total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) < 5 x (<10 x if taking steroids) the institutional upper limit of normal; creatinine within normal institutional limits for age OR creatinine clearance > 60mL/min/1.73 m for patients with creatinine levels above institutional normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arthur M Blank Hospital · Atlanta, Georgia
- Children's Healthcare of Atlanta: Scottish Rite · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06624371 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior atovaquone disqualifies patients from enrollment.
Does this trial require H3-3A?
Yes, H3-3A K27M mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify